Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
Aditxt, Inc. reported amendments to its merger agreement with Evofem Biosciences and outlined a series of parent equity investments tied to that transaction. The company agreed to purchase incremental shares of Evofem's Series F-1 Preferred Stock in staged investments: $500,000 on or before July 12, 2024, $500,000 on August 9, 2024, a later-scheduled Third investment that was amended several times and ultimately adjusted to $720,000 with an October 2, 2024 target, and a Fourth investment increased to $2.28 million with later deadlines moved into late 2024 and 2025. Multiple amendments also extended the merger End Date to September 30, 2025, and the parties agreed Evofem will use commercially reasonable efforts to hold the Company Shareholders Meeting no later than September 26, 2025. The Company additionally agreed to invest $1,500,000 in Evofem no later than April 7, 2025 in exchange for additional F-1 Preferred Stock and/or, at the Company's option, senior subordinated notes.
Aditxt, Inc. filed a sixth amendment to a prior current report to add more detailed financial information related to its acquisition of Evofem Biosciences. This amendment includes Evofem’s unaudited condensed consolidated financial statements as of June 30, 2025 and December 31, 2024, and results for the three and six months ended June 30, 2025 and 2024. It also provides unaudited pro forma condensed consolidated combined financial information for Aditxt and Evofem for the six months ended June 30, 2025, showing how the combined company’s finances would have looked over that period.
The company notes that the pro forma information is for informational purposes only and is not a prediction of future performance. This amendment does not change any other part of the original report or discuss new developments at Aditxt or its subsidiaries beyond supplying these Evofem-related financial statements.
Aditxt announced that its CEO presented at the Wall Street Reporter Next Super Stock livestream and the company furnished a transcript as Exhibit 99.1. The filing makes the transcript available to investors and notes an archived audio recording will be accessible for 30 days on the company’s Investor Relations website. The filing includes a caution that the transcript may contain errors and that the presentation contains forward-looking statements.
The forward-looking disclosures explicitly reference the proposed initial public offering of Pearsanta and Aditxt’s planned acquisition of Evofem as matters subject to risk, and the company warns that actual results may differ materially from those statements.
Aditxt, Inc. (ADTX) is soliciting proxies for its 2025 annual meeting to be held virtually on September 16, 2025 at 12:00 PM ET. Stockholders of record as of August 8, 2025 (4,956,555 shares outstanding) may vote on four items: election of five directors, ratification of dbb mckennon as independent registered public accounting firm for fiscal 2025, authorization to grant the board discretionary authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-250 to be effective within one year if approved, and authorization to adjourn the meeting if needed.
The board proposes five nominees (Amro Albanna, Shahrokh Shabahang, Brian Brady, Charles Nelson, and Sylvia Hermina) and discloses board composition changes as two directors (Jeffrey Runge and Saundra Pelletier) are not standing for re-election, reducing the board from seven to five. Executive officer pay tables list 2024 base salaries including the CEO at $500,000 and other named officers. The proxy explains voting procedures, quorum (1,652,185 shares), broker voting rules, committee compositions, and director independence assessments consistent with Nasdaq standards.
Aditxt, Inc. (ADTX) disclosed two board members, Dr. Jeffrey Runge and Saundra Pelletier, will not stand for reelection at the 2025 Annual Meeting but will continue to serve until their terms expire. The company stated these decisions were not due to any disagreements with the company on operations, policies or practices.
The Board set the 2025 Annual Meeting for September 16, 2025 to be held virtually, with a record date of August 8, 2025. Because the meeting date changed by more than 30 days from last year, the prior proxy-statement nomination deadline no longer applies; the company established a submission deadline of August 18, 2025 for Rule 14a-8 proposals and for director nominations.
The filing also notes governance changes: the Board will be reduced from seven to five members after the meeting, and the company reiterated that Ms. Pelletier is expected to be appointed to the Board and as President of Adifem following the closing of the previously disclosed merger with Evofem per the Amended and Restated Merger Agreement dated July 12, 2024. The report includes a cautionary note that the proposed transaction may not be completed and lists related risks.